Health Care Sector Equities Ahead of Market -- Research on MannKind, Merrimack Pharma, AVEO Pharma, and Rexahn Pharma

LONDON, June 26, 2014 /PRNewswire/ --

On Wednesday, June 25, 2014, the NASDAQ Composite ended at 4,379.76, up 0.68%, the Dow Jones Industrial Average advanced 0.29%, to finish the day at 16,867.51, and the S&P 500 closed at 1,959.53, up 0.49%. The gains were broad based with nine out of ten sectors ending the session in positive. The S&P 500 Health Care Sector Index ended the day at 708.15, up 1.08%, with the index advancing 5.43% in the previous three months. Investor-Edge has initiated coverage on the following equities: MannKind Corp. (NASDAQ: MNKD), Merrimack Pharmaceuticals Inc. (NASDAQ: MACK), AVEO Pharmaceuticals Inc. (NASDAQ: AVEO) and Rexahn Pharmaceuticals Inc. (NYSE MKT: RNN). Free technical research on MNKD, MACK, AVEO and RNN can be downloaded upon signing up at:

http://www.investor-edge.com/4230-register

On Wednesday, MannKind Corp.'s stock edged 0.09% lower, to close the day at $10.59. The stock recorded a trading volume of 6.03 million shares, much below its three months average volume of 12.02 million shares. The company shares oscillated between $10.36 and $10.68 during the session. Over the last one month and over the past three trading months, MannKind Corp.'s shares have rallied 36.29% and 82.59%, respectively. Further, the stock has gained an upside of 103.65% since the start of this year. The company's shares are trading above their 50-day and 200-day moving averages. Moreover, the stock's 50-day moving average of $8.02 is greater than its 200-day moving average of $6.14. MannKind Corp.'s stock has a Relative Strength Index (RSI) of 66.71. Sign up today to read free research on MNKD at:

http://www.investor-edge.com/4230-MNKD-26Jun2014.pdf

On Wednesday, shares in Merrimack Pharmaceuticals Inc. recorded a trading volume of 1.38 million shares, lower than its three months average volume of 2.24 million shares. The stock ended the day at $7.44, which was 3.91% above its previous day's closing of $7.16, and registered an intraday range of $7.04 and $7.55. Although Merrimack Pharmaceuticals Inc.'s stock has lost 1.06% in the last one month, it has gained 6.29% in the previous three trading sessions and 39.56% on YTD basis. The company's stock is trading above its 50-day and 200-day moving averages of $6.63 and $5.04, respectively. Furthermore, shares of Merrimack Pharmaceuticals Inc. have an RSI of 47.66. Sign up today to read free research on MACK at:

http://www.investor-edge.com/4230-MACK-26Jun2014.pdf

AVEO Pharmaceuticals Inc.'s stock finished the Wednesday's session 0.32% higher at $1.58. A total of 0.90 million shares were traded, close to its three months average volume of 0.86 million shares. The stock vacillated between $1.56 and $1.65 during the session. Over the previous three trading sessions and over the last one month, AVEO Pharmaceuticals Inc.'s shares have surged 3.27% and 47.66%, respectively. However, from the beginning of 2014, the company's stock has fallen by 13.66%. The stock is trading above its 50-day moving average of $1.24, while the 50-day moving average is below its 200-day moving average of $1.73. Additionally, AVEO Pharmaceuticals Inc.'s stock has an RSI of 71.36. Sign up today to read free research on AVEO at:

http://www.investor-edge.com/4230-AVEO-26Jun2014.pdf

On Wednesday, shares in Rexahn Pharmaceuticals Inc. fluctuated between $0.84 and $0.87 before ending the session 0.47% lower at $0.86. The stock reported a trading volume of 1.41 million shares, below its three months average volume of 3.38 million shares. Rexahn Pharmaceuticals Inc.'s shares have fallen by 0.47% in the previous three trading sessions and 4.93% in the last one month, while the stock has surged 67.84% on YTD basis. The company's shares are trading above their 200-day moving average. Moreover, the stock's 50-day moving average of $0.91 is greater than its 200-day moving average of $0.80. Shares of Rexahn Pharmaceuticals Inc. have an RSI of 42.00. Sign up today to read free research on RNN at:

http://www.investor-edge.com/4230-RNN-26Jun2014.pdf


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.investor-edge.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.investor-edge.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.investor-edge.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-Edge, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Investor-Edge in this article or report according to the procedures outlined by Investor-Edge. Investor-Edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Investor-Edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Investor-Edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-Edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-Edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-Edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Investor-Edge

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED